^
    CANCER:

    Esophageal Squamous Cell Carcinoma





    Show legend
    Group by Gene:
    Include preclinical:

    nivolumab
    sintilimab
    tislelizumab
    toripalimab-tpzi
    		0
    PD1 inhibitor
    pembrolizumab
    PD1 inhibitor
    serplulimab
    zimberelimab
    camrelizumab
    1
    PD-L1 inhibitor
    sugemalimab
    atezolizumab
    2
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    3
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    4
    EGFR inhibitor
    erlotinib
    nimotuzumab
    5
    DNA synthesis inhibitor
    cisplatin
    nedaplatin
    6
    VEGFR inhibitor, FGFR1 inhibitor, PD1 inhibitor
    toripalimab-tpzi + surufatinib
    7
    VEGFR-2 inhibitor
    rivoceranib
    8
    pan-HER inhibitor
    Z650
    9
    DKK1 protein inhibitor
    DKN-01
    10
    RET inhibitor
    selpercatinib
    11
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    12
    HER2 inhibitor
    trastuzumab
    13
    HER3 inhibitor
    AV-203
    14
    DKK1 protein inhibitor, PD1 inhibitor
    pembrolizumab + DKN-01
    15
    EGFR antagonist
    SCT200
    16
    TIGIT inhibitor, PD1 inhibitor
    tislelizumab + BGB-A1217
    17
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    18
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + 5-fluorouracil
    19
    Immunotherapy
    Immunotherapy
    20
    Chemotherapy
    FOLFOX
    FP
    21
    MUC1-targeted antibody-drug conjugate, Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    M1231
    22
    B7-H3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    DS-7300
    23
    KRAS G12C inhibitor
    RG6330
    24
    Multi-tyrosine kinase inhibitor
    anlotinib
    25
    mTORC1 inhibitor
    nanoparticle albumin-bound rapamycin
    26
    C4.4a-targeted antibody-drug conjugate, Microtubule inhibitor
    BAY1129980
    27
    AMPK activator
    metformin
    28
    YES1 inhibitor, Src kinase inhibitor
    NXP900
    29
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    LR004-VC-MMAE
    30
    GPC-1-targeted antibody-drug conjugate
    anti-GPC-1 ADC
    No biomarker
    PD-L1 expression
    PD-L1 overexpression
    PD-L1 underexpression
    HER-2 negative
    HER-2 positive
    EGFR overexpression
    EGFR amplification
    EGFR mutation
    DKK1 overexpression
    LGALS1 underexpression
    IFNG-L
    LAMP3-L
    LGALS1 elevation
    IFNG overexpression
    LAMP3 overexpression
    FOXP3 overexpression
    TTN D7145H
    PD-L1 overexpression + CCL5 overexpression
    KDR expression
    TP53 mutation
    NFKB1 expression
    CD73 underexpression
    NTRK3 fusion
    CD276 overexpression
    NRG1 overexpression
    MUC1 expression + EGFR expression
    CXCL5 overexpression
    CCL19 underexpression
    UMODL1 underexpression
    BRCA1 mutation
    TIGIT expression
    BRAF V600E
    MYH4 Q1210fs
    CD8 expression
    PD-1 expression
    SLFN11 expression
    NTRK1 fusion
    TMB-H
    LDH elevation
    RET fusion
    NTRK2 fusion
    COL19A1 overexpression
    PD-1 expression + CD8 expression
    TLR signature
    GPC1 expression
    YES1 amplification
    HSPA6 expression
    CDK14 overexpression
    MACC1-AS1 overexpression
    PARP1 expression
    NDRG1 overexpression
    CD31 expression
    BAX expression
    SOX9 overexpression
    SGK1 overexpression
    LYPD3 expression
    PER2 underexpression
    CD44 overexpression + CD24 underexpression
    AFAP1-AS1 overexpression
    UBQLN4 overexpression
    MRE11A underexpression
    BRCA2 mutation